Autolus Therapeutics Highlights Advancing Autoimmune Pipeline at
AUTL Stock | USD 2.38 0.03 1.28% |
About 55% of Autolus Therapeutics' institutional investors are presently thinking to get in. The analysis of overall sentiment of trading Autolus Therapeutics stock suggests that some investors are interested at this time. Autolus Therapeutics' investing sentiment shows overall attitude of investors towards Autolus Therapeutics.
Company outlined potential for value creation driven by obe-cel across multiple B cell driven malignancies and autoimmune diseases, including acute lymphoblasti
Read at gurufocus.com
![]() |
Autolus Therapeutics Fundamental Analysis
We analyze Autolus Therapeutics' financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Autolus Therapeutics using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Autolus Therapeutics based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Current Ratio
Current Ratio Comparative Analysis
Autolus Therapeutics is currently under evaluation in current ratio category among its peers. Current Ratio is calculated by dividing the Current Assets of a company by its Current Liabilities. It measures whether or not a company has enough cash or liquid assets to pay its current liability over the next fiscal year. The ratio is regarded as a test of liquidity for a company.
Autolus Therapeutics Potential Pair-trading
One of the popular trading techniques among algorithmic traders is to use market-neutral strategies where every trade hedges away some risk. Because there are two separate transactions required, even if one position performs unexpectedly, the other equity can make up some of the losses. Below are some of the equities that can be combined with Autolus Therapeutics stock to make a market-neutral strategy. Peer analysis of Autolus Therapeutics could also be used in its relative valuation, which is a method of valuing Autolus Therapeutics by comparing valuation metrics with similar companies.
Peers
Autolus Therapeutics Related Equities
TECX | Tectonic Therapeutic, | 6.47 | ||||
CRNX | Crinetics Pharmaceuticals | 3.61 | ||||
DAWN | Day One | 2.08 | ||||
KZR | Kezar Life | 0.73 |
Check out Autolus Therapeutics Hype Analysis, Autolus Therapeutics Correlation and Autolus Therapeutics Performance. For more information on how to buy Autolus Stock please use our How to buy in Autolus Stock guide.You can also try the Performance Analysis module to check effects of mean-variance optimization against your current asset allocation.
Is Pharmaceutical Products space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Autolus Therapeutics. If investors know Autolus will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Autolus Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
The market value of Autolus Therapeutics is measured differently than its book value, which is the value of Autolus that is recorded on the company's balance sheet. Investors also form their own opinion of Autolus Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Autolus Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Autolus Therapeutics' market value can be influenced by many factors that don't directly affect Autolus Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Autolus Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Autolus Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Autolus Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.